Analyst firms · Morgan Stanley · RPRX

Morgan Stanley RPRX price target and rating history

Royalty Pharma plc (RPRX) · Health Care

Morgan Stanley rates Royalty Pharma plc (RPRX) Overweight with a $51 price target, as of its latest action on May 16, 2025. It has published 3 rating actions on RPRX since August 2021, including 0 upgrades and 0 downgrades.

Current rating
Overweight
Price target
$51
Median target, all firms
Too few
Actions on RPRX
3

Morgan Stanley price target on RPRX

$51$49$4620222023202420252026
Morgan Stanley price target on RPRX, each point a stated target, August 2021 to May 2025.

Every Morgan Stanley rating on RPRX

Questions about Morgan Stanley and RPRX

What is Morgan Stanley's price target for RPRX?
Morgan Stanley's latest stated price target for Royalty Pharma plc (RPRX) is $51, from its action on May 16, 2025.
What is Morgan Stanley's rating on RPRX?
Morgan Stanley rates RPRX Overweight, a bullish rating, as of May 16, 2025.
When did Morgan Stanley last change its view on RPRX?
On May 16, 2025, Morgan Stanley starts coverage at Overweight, price target $51.

More RPRX rating histories

All Morgan Stanley ratingsRPRX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.